These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 22094831)

  • 1. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity.
    Seidl A; Hainzl O; Richter M; Fischer R; Böhm S; Deutel B; Hartinger M; Windisch J; Casadevall N; London GM; Macdougall I
    Pharm Res; 2012 Jun; 29(6):1454-67. PubMed ID: 22094831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stability of multidose, preserved formulation epoetin alfa in syringes for three and six weeks.
    Naughton CA; Duppong LM; Forbes KD; Sehgal I
    Am J Health Syst Pharm; 2003 Mar; 60(5):464-8. PubMed ID: 12635452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of illegal trade on the quality of epoetin alfa in Thailand.
    Fotiou F; Aravind S; Wang PP; Nerapusee O
    Clin Ther; 2009 Feb; 31(2):336-46. PubMed ID: 19302906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Micelle-associated protein in epoetin formulations: aA risk factor for immunogenicity?
    Hermeling S; Schellekens H; Crommelin DJ; Jiskoot W
    Pharm Res; 2003 Dec; 20(12):1903-7. PubMed ID: 14725351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein isolated from biopharmaceutical formulations cannot be used for comparative studies: Follow-up to "a case study using Epoetin Alfa from Epogen and EPREX".
    Heavner GA; Arakawa T; Philo JS; Calmann MA; Labrenz S
    J Pharm Sci; 2007 Dec; 96(12):3214-25. PubMed ID: 17721976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study.
    Haag-Weber M; Eckardt KU; Hörl WH; Roger SD; Vetter A; Roth K
    Clin Nephrol; 2012 Jan; 77(1):8-17. PubMed ID: 22185963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reaction to the paper: interaction of polysorbate 80 with erythropoietin: a case study in protein-surfactant interactions.
    Hermeling S; Jiskoot W; Crommelin DJ; Schellekens H
    Pharm Res; 2006 Mar; 23(3):641-2; author reply 643-4. PubMed ID: 16525860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigating Serious Adverse Drug Reactions in Patients Receiving Erythropoiesis-Stimulating Agents: A Root Cause Analysis Using the "ANTICIPATE" Framework.
    Jacob S; Nichols J; Macdougall IC; Qureshi Z; Chen B; Yang YT; Norris LB; Bennett CL
    Am J Ther; 2018; 25(6):e670-e674. PubMed ID: 30169374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Protein Aggregating Tungstates: Electrospray Mass Spectrometry Analysis of Extracts from Prefilled Syringes and from Tungsten Pins Used in the Manufacture of Syringes.
    Ronk M; Lee H; Fujimori K; Yeh P; Nashed-Samuel Y
    PDA J Pharm Sci Technol; 2016; 70(1):51-61. PubMed ID: 26797967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced drug costs from switching hemodialysis patients from epoetin alfa in multidose vials to pre-filled syringes.
    Wazny LD; Raymond CB; Do MK; Skwarchuk DE
    CANNT J; 2009; 19(3):39-41. PubMed ID: 19899498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recognition and identification of UV-absorbing leachables in EPREX pre-filled syringes: an unexpected occurrence at a formulation-component interface.
    Pang J; Blanc T; Brown J; Labrenz S; Villalobos A; Depaolis A; Gunturi S; Grossman S; Lisi P; Heavner GA
    PDA J Pharm Sci Technol; 2007; 61(6):423-32. PubMed ID: 18410043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: a randomized prospective study.
    Lissy M; Ode M; Roth K
    Drugs R D; 2011; 11(1):61-75. PubMed ID: 21410296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C.
    Stravitz RT; Chung H; Sterling RK; Luketic VA; Sanyal AJ; Price AS; Purrington A; Shiffman ML
    Am J Gastroenterol; 2005 Jun; 100(6):1415-9. PubMed ID: 15929778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin.
    Casadevall N
    Nephrol Dial Transplant; 2003 Nov; 18 Suppl 8():viii37-41. PubMed ID: 14608000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights.
    Macdougall IC; Roger SD; de Francisco A; Goldsmith DJ; Schellekens H; Ebbers H; Jelkmann W; London G; Casadevall N; Hörl WH; Kemeny DM; Pollock C
    Kidney Int; 2012 Apr; 81(8):727-32. PubMed ID: 22336988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical assessment of erythropoietin products from Asia versus US Epoetin alfa manufactured by Amgen.
    Park SS; Park J; Ko J; Chen L; Meriage D; Crouse-Zeineddini J; Wong W; Kerwin BA
    J Pharm Sci; 2009 May; 98(5):1688-99. PubMed ID: 18781649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin-coated ZP-microneedle transdermal system: preclinical formulation, stability, and delivery.
    Peters EE; Ameri M; Wang X; Maa YF; Daddona PE
    Pharm Res; 2012 Jun; 29(6):1618-26. PubMed ID: 22258935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Root Cause Analysis of Tungsten-Induced Protein Aggregation in Pre-filled Syringes.
    Liu W; Swift R; Torraca G; Nashed-Samuel Y; Wen ZQ; Jiang Y; Vance A; Mire-Sluis A; Freund E; Davis J; Narhi L
    PDA J Pharm Sci Technol; 2010; 64(1):11-9. PubMed ID: 21501999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability, potency, and preservative effectiveness of epoetin alfa after addition of a bacteriostatic diluent.
    Corbo DC; Suddith RL; Sharma B; Naso RB
    Am J Hosp Pharm; 1992 Jun; 49(6):1455-8. PubMed ID: 1529989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties.
    Storring PL; Tiplady RJ; Gaines Das RE; Stenning BE; Lamikanra A; Rafferty B; Lee J
    Br J Haematol; 1998 Jan; 100(1):79-89. PubMed ID: 9450795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.